Back to mobile site

Exact Sciences (EXAS) Tops Q2 EPS by 25c, provides guidance

July 31, 2024 4:14 PM EDT

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.09), $0.25 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $699.26 million versus the consensus estimate of $690.01 million.

GUIDANCE:

Exact Sciences sees FY2024 revenue of $2.81-2.85 billion, versus the consensus of $2.83 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings, Maynard Um, Mark Zuckerberg, ARK